Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
News|Articles|December 13, 2012
NABP with state boards create action plan to help enforce compounding regulations
Last week, NABP Executive Director Carmen Catizone, MS, RPh, unveiled an action plan to inspect nonresident compounding pharmacies and create a database to share regulatory information about these pharmacies with the state boards of pharmacy nationwide. This was in response to the fungal meningitis outbreak that took the lives of 37 individuals and injured 590.
Advertisement
Advertisement
Related to this article
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.
A truly transparent PBM arrangement starts with full disclosure of direct and indirect compensation.
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.
Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Liver MRI marker tied to lower quality of life in MASH, trial finds
2
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
5